Eisai Co. Ltd.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.
The item "Total-Cashflows-From-Financing-Activities" stands at -4.76 Billion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 03/31/2023.
Eisai Co. Ltd.'s second quarter result of -6.18 Billion JPY for the item "Total Cashflows From Financing Activities" represents a decrease of -123.68 percent compared to it's first quarter result.
Also, Eisai Co. Ltd.'s second quarter result of -6.18 Billion JPY for the item "Total Cashflows From Financing Activities" represents an increase of 70.90 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Eisai Co. Ltd.'s second quarter result of -4.76 Billion JPY for the item "Total Cashflows From Financing Activities" represents an increase of 75.96 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 30.10 Billion Japanese Yens compared to the value the year prior.
The 1 year change is 30.10 Billion Japanese Yens.
The 3 year change is 44.06 Billion Japanese Yens.
The 5 year change is 76.52 Billion Japanese Yens.
The 10 year change is 65.46 Billion Japanese Yens.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Total Cashflows From Financing Activities | 905,699,262,464.00 |
![]() | Johnson & Johnson - Total Cashflows From Financing Activities | 486,508,953,600.00 |
![]() | AbbVie Inc - Total Cashflows From Financing Activities | 399,570,305,024.00 |
![]() | Roche Holding AG - Total Cashflows From Financing Activities | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Total Cashflows From Financing Activities | 280,205,508,085.11 |